Compare DEO & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEO | ZTS |
|---|---|---|
| Founded | 1886 | 1952 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6B | 53.9B |
| IPO Year | N/A | 2013 |
| Metric | DEO | ZTS |
|---|---|---|
| Price | $86.99 | $125.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $109.00 | ★ $174.60 |
| AVG Volume (30 Days) | 1.7M | ★ 6.0M |
| Earning Date | 02-03-2026 | 02-12-2026 |
| Dividend Yield | ★ 4.72% | 1.69% |
| EPS Growth | N/A | ★ 11.64 |
| EPS | 1.06 | ★ 5.94 |
| Revenue | ★ $20,245,000,000.00 | $9,397,000,000.00 |
| Revenue This Year | $2.58 | $3.04 |
| Revenue Next Year | $3.33 | $4.98 |
| P/E Ratio | $81.62 | ★ $21.19 |
| Revenue Growth | N/A | ★ 2.68 |
| 52 Week Low | $85.12 | $115.25 |
| 52 Week High | $127.33 | $177.40 |
| Indicator | DEO | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 55.97 |
| Support Level | $85.48 | $125.45 |
| Resistance Level | $86.94 | $127.60 |
| Average True Range (ATR) | 1.18 | 2.46 |
| MACD | 0.09 | 0.89 |
| Stochastic Oscillator | 39.02 | 83.71 |
Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio. The firm has also shed noncore brands over the years, including the majority of its wine assets in 2015.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.